A study on the efficacy and safety of aprepitant injection in preventing and treating nausea and vomiting induced by platinum‐based chemotherapy in lung cancer

Abstract

Abstract This study aimed to assess the clinical efficacy and safety of aprepitant injection in preventing and treating nausea and vomiting induced by platinum‐based chemotherapy in lung cancer patients. Forty‐eight patients with advanced first‐line lung cancer undergoing cisplatin‐ or carboplatin‐based chemotherapy were randomly assigned to either the experimental group or the control group, with 24 patients in each group. The control group received dexamethasone and palonosetron for vomiting prevention, whereas the experimental group received dexamethasone, palonosetron, and aprepitant injection. The study compared the incidence of acute and delayed vomiting, functional life index (FLIE) scores for nausea and vomiting at 24 and 120 h postchemotherapy and the occurrence of adverse drug reactions between the two groups. The effective control rate of acute‐phase vomiting in the treatment group was 83.33%, significantly higher than 45.83% in the control group, with a statistically significant difference (p .05). Aprepitant injection effectively prevents platinum‐based chemotherapy‐induced nausea and vomiting, enhances patients' quality of life, and demonstrates good safety, justifying its clinical adoption.

Keywords

• aprepitant injection
• lung cancer
• prophylactic antiemetic